TriangleJNJ-101556143 (NCT07832292)
JNJ-101556143 trial for Prostatic Neoplasms (NCT07832292). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with progressive metastatic prostate adenocarcinoma despite testosterone suppression. PSA must be at least ten nanograms per milliliter; certain neuroendocrine and other prostate-cancer types are excluded.
The idea: test daily oral JNJ-101556143, an investigational drug targeting the androgen receptor, in repeating four-week cycles. Testosterone-suppressing treatment continues unless both testes were removed. Researchers measure tumor shrinkage or disappearance and monitor safety. There is one treatment group, and treatment continues until progression or another stopping criterion.
This phase 2 study plans 100 patients. Janssen sponsors four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.